Preclinical efficacy data of MGN1601, a tumor vaccine comprising 4-fold gene-modified and irradiated allogeneic tumor cells in combination with a DNA-based immunomodulator for the treatment of metastatic renal carcinoma

Authors :: Barbara Volz
Marina Tschaika
Burghardt Wittig
Matthias Schroff
Kerstin Kapp
Martina Schmidt
Source :: Journal of Clinical Oncology. 28:e15067-e15067
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e15067 Background: MGN1601 is a cell-based tumor vaccine for the treatment of mRCC. MGN1601 consists of two active pharmaceutical ingredients. One consists of allogeneic, human tumor cells, derived...

Subjects :: Active ingredient
Cancer Research
Pathology
medicine.medical_specialty
business.industry
Cell
Tumor cells
urologic and male genital diseases
Human tumor
medicine.anatomical_structure
Oncology
medicine
Cancer research
Metastatic renal carcinoma
business
Gene

Tools